Your browser doesn't support javascript.
loading
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.
Lander, Eric M; Rappazzo, Katherine C; Huang, Li-Ching; Hu, Jiun-Ruey; Chen, Heidi; Shyr, Yu; Abramson, Vandana G.
Afiliação
  • Lander EM; Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
  • Rappazzo KC; Department of Hematology/Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Huang LC; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.
  • Hu JR; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Chen H; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.
  • Shyr Y; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.
  • Abramson VG; Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
Oncologist ; 28(2): 123-130, 2023 02 08.
Article em En | MEDLINE | ID: mdl-36495309

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia Neoadjuvante Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Oncologist Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia Neoadjuvante Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Oncologist Ano de publicação: 2023 Tipo de documento: Article